Allena Pharmaceuticals Inc. (ALNA)’s Financial Results Comparing With Xenetic Biosciences Inc. (NASDAQ:XBIO)

As Biotechnology companies, Allena Pharmaceuticals Inc. (NASDAQ:ALNA) and Xenetic Biosciences Inc. (NASDAQ:XBIO) are our subject to contrast. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allena Pharmaceuticals Inc. 2 0.00 9.05M -2.12 0.00
Xenetic Biosciences Inc. 1 0.00 4.38M -12.77 0.00

Demonstrates Allena Pharmaceuticals Inc. and Xenetic Biosciences Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Allena Pharmaceuticals Inc. 388,412,017.17% -120.8% -84.3%
Xenetic Biosciences Inc. 312,165,918.32% -148% -106.8%

Liquidity

The Current Ratio of Allena Pharmaceuticals Inc. is 4 while its Quick Ratio stands at 4. The Current Ratio of rival Xenetic Biosciences Inc. is 7.6 and its Quick Ratio is has 7.6. Xenetic Biosciences Inc. is better equipped to clear short and long-term obligations than Allena Pharmaceuticals Inc.

Analyst Ratings

Allena Pharmaceuticals Inc. and Xenetic Biosciences Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allena Pharmaceuticals Inc. 0 1 0 2.00
Xenetic Biosciences Inc. 0 0 0 0.00

Allena Pharmaceuticals Inc.’s average target price is $4, while its potential upside is 49.81%.

Institutional & Insider Ownership

Roughly 82% of Allena Pharmaceuticals Inc. shares are held by institutional investors while 22.6% of Xenetic Biosciences Inc. are owned by institutional investors. Allena Pharmaceuticals Inc.’s share held by insiders are 8.27%. Insiders Competitively, held 4.9% of Xenetic Biosciences Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allena Pharmaceuticals Inc. -13.57% -67.35% -54.74% -55.89% -79.1% -64.95%
Xenetic Biosciences Inc. 8.13% 4.72% -10.14% -86.32% -95.97% -93.24%

For the past year Allena Pharmaceuticals Inc.’s stock price has smaller decline than Xenetic Biosciences Inc.

Summary

Allena Pharmaceuticals Inc. beats on 9 of the 10 factors Xenetic Biosciences Inc.

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The companyÂ’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.